Effects of a milk product, fermented by Lactobacillus acidophilus and with fructo-oligosaccharides added, on blood lipids in male volunteers

Schaafsma, G.; Meuling, W.J.A.; Dokkum, W. van; Bouley, Christine

doi:10.1038/sj.ejcn.1600583

Cited by 164 publications

(101 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The preponderance of fermented milk interventions (Agerback et al, 1995;Schaafsma et al, 1998;Bertolami et al, 1999;Xiao et al, 2003) compared to capsule interventions (Hlivak et al, 2005) demonstrating a hypocholesterolemic effect supports the concept that a dairy medium may be the most efficacious route of administering probiotic bacteria. In vitro simulation has suggested that whereas some species of L. and B. lose viability during gastric transit, ingestion with milk proteins improves their tolerance to the pH of upper GI system (Charteris, 1998).…”

Section: Discussionmentioning

confidence: 97%

“…The dose was intended to maximize the potential for a lipid-lowering effect; however, it may have been insufficient. Although an investigation providing a dose of 10 9 CFU of probiotic bacteria via a daily capsule achieved a hypocholesterolemic effect (Hlivak et al, 2005), fermented milk studies demonstrating an effect (Agerback et al, 1995;Schaafsma et al, 1998;Bertolami et al, 1999;Xiao et al, 2003) administered 200-300 ml of product containing 10 7 -10 9 CFU per ml for a total dose of 10 9 -10 11 CFU.…”

Section: Discussionmentioning

confidence: 99%

“…Although most studies have reported a hypocholesterolemic effect (Agerback et al, 1995;Schaafsma et al, 1998;Bertolami et al, 1999;Xiao et al, 2003), not all investigations support this result (Richelsen et al, 1996;de Roos et al, 1999). The logistics of procuring and storing a fermented milk product for daily consumption and the dietary modification required to accommodate the additional calories contained in fermented milk products have prompted an exploration of alternative methods for ingesting probiotic bacteria.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Probiotic capsules do not lower plasma lipids in young women and men

et al. 2007

View full text Add to dashboard Cite

Objective: To investigate the effect of probiotic capsules on plasma lipids. Design: A randomized, single-blinded, placebo-controlled, parallel-arm trial. Subjects: Fifty-five normocholesterolemic subjects ages 18-36 (33 premenopausal women and 22 men). Intervention: Each subject consumed either three probiotic capsules each containing a total of 10 9 colony-forming units Lactobacillus acidophilus and Bifidobacterium longum and 10-15 mg fructo-oligosaccharide or three placebo capsules daily for 2 months (men) or two menstrual cycles (women). Plasma lipids were measured before and following the intervention (during the early follicular phase for women). Results: Plasma concentrations of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglyceride were not altered by consumption of probiotic or placebo capsules and were not different between treatment groups following the intervention. Conclusions: These results do not support a beneficial effect of Lactobacillus acidophilus strain DDS-1 and Bifidobacterium longum strain UABL-14 on plasma lipids in normocholesterolemic young women and men. Sponsorship: Supported by the Minnesota Agricultural Experiment Station and UAS Laboratories.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Probiotic capsules do not lower plasma lipids in young women and men

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Fat, protein and dry matter intake did not differ significantly between the placebo and the probiotic periods (Table 2). Earlier studies dealing with the influence of probiotics on cholesterol metabolism have shown contradictory results (Schaafsma et al, 1998;AgerholmLarsen et al, 2000;Jahreis et al, 2002;Kie ling et al, 2002;Lewis and Burmeister, 2005). These contradictions might be caused by different strains and amounts of administered probiotic cultures, no standardized application forms (milk products, sausage and capsules) and varying lengths of treatment periods.…”

Section: Discussionmentioning

confidence: 99%

Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults

Friedrich²,

et al. 2007

View full text Add to dashboard Cite

Objective: It was determined whether a combination of Lactobacillus acidophilus (L. acidophilus) 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 (B. lactis 420) affect the faecal microbiota as well as immunological parameters and blood lipids in healthy adults. Design: A placebo-controlled, double-blinded, randomized crossover trial was conducted. Subjects: Twenty-six healthy volunteers (mean age 25 years) were recruited by advertising in academical buildings. All of them completed the study. Methods: After 3-week run-in period, half of the volunteers consumed 300 g/day of yoghurt supplement containing probiotic strains L. acidophilus 74-2 and B. lactis 420, and the other half received the placebo product for a period of 5 weeks. The two groups were crossed during the following 5-week period. Blood and faecal samples were collected at the end of each period. The faecal content of probiotic bacteria, faecal short-chain fatty acids (SCFA), serum lipids and plasma immune system biomarkers were evaluated. Results: Faecal proportions of L. acidophilus and of B. lactis increased significantly from 0.02 to 0.19 and 0.4 to 1.4% (Po0.05), respectively. Percentages of granulocytes and monocytes showing phagocytic activity were significantly elevated from 92 to 95% during probiotic intervention, whereas their oxidative burst activity and specific immune parameters remained unaffected. Fecal SCFA and serum cholesterol levels were not influenced by the probiotics. However, serum concentrations of triacylglyceroles decreased significantly by 11.6% (Po0.05) in the probiotic supplementation period. Conclusions: L. acidophilus and B. lactis were recovered in faeces in significantly elevated numbers after supplementation. They are able to modulate unspecific cellular immune response indicated by the increased phagocytic activity.

show abstract

“…[15][16][17][18][19] The majority of randomized controlled trials, however, have reported no significant effect, [20][21][22][23][24][25] and no clinical trial has reported significant LDL-C reductions of a probiotic supplement formulation unless delivered as a synbiotic. 26 Previously, we have reported on the cholesterollowering efficacy of a microencapsulated BSH-active Lactobacillus reuteri NCIMB 30242 yogurt formulation.…”

Section: Introductionmentioning

confidence: 99%

Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial

2012

View full text Add to dashboard Cite

BACKGROUND/OBJECTIVES:The percentage of hypercholesterolemic individuals not reaching their LDL-cholesterol (LDL-C) goal remains high and additional therapeutic strategies should be evaluated. The objective of this study was to evaluate the cholesterollowering efficacy and mechanism of action of bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 capsules in hypercholesterolemic adults. SUBJECTS/METHODS: A total of 127 subjects completed a randomized, double-blind, placebo-controlled, parallel-arm, multicenter study. Subjects were randomized to consume L. reuteri NCIMB 30242 capsules or placebo capsules over a 9-week intervention period. The primary outcome was LDL-C relative to placebo at the study end point. RESULTS: L. reuteri NCIMB 30242 capsules reduced LDL-C by 11.64% (Po0.001), total cholesterol by 9.14%, (Po0.001), non-HDLcholesterol (non-HDL-C) by 11.30% (Po0.001) and apoB-100 by 8.41% (P ¼ 0.002) relative to placebo. The ratios of LDL-C/HDLcholesterol (HDL-C) and apoB-100/apoA-1 were reduced by 13.39% (P ¼ 0.006) and 9.00% (P ¼ 0.026), respectively, relative to placebo. Triglycerides and HDL-C were unchanged. High-sensitivity C-reactive protein and fibrinogen were reduced by 1.05 mg/l (P ¼ 0.005) and 14.25% (P ¼ 0.004) relative to placebo, respectively. Mean plasma deconjugated bile acids were increased by 1.00 mmol/l (P ¼ 0.025) relative to placebo, whereas plasma campesterol, sitosterol and stigmasterol were decreased by 41.5%, 34.2% and 40.7%, respectively. CONCLUSIONS: The present results suggest that the deconjugation of intraluminal bile acids results in reduced absorption of non-cholesterol sterols and indicate that L. reuteri NCIMB 30242 capsules may be useful as an adjunctive therapy for treating hypercholesterolemia.

show abstract

Effects of a milk product, fermented by Lactobacillus acidophilus and with fructo-oligosaccharides added, on blood lipids in male volunteers

Abstract: As compared to traditional yogurt, daily consumption of three times 125 ml of test product specifically lowered serum LDL-cholesterol levels in normal healthy male adult subjects with borderline elevated levels of serum total cholesterol within three weeks.

Cited by 164 publications

References 12 publications

Probiotic capsules do not lower plasma lipids in young women and men

Probiotic capsules do not lower plasma lipids in young women and men

Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults

Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial

Contact Info

Product

Resources

About